Dataset Information

Ovarian Cancer Proteomics of FFPE Tissue

ABSTRACT: We have performed in-depth examination of single tissue sections from a collection of FFPE and Frozen treated tumors, as well as cell line material all originating from different subtypes of epithelial ovarian cancer (high-grade serous, clear cell, endometrioid). Data were prepared using a tandem mass tag 10plex protocol with MS3 analysis on an Orbitrap Fusion.

INSTRUMENT(S): Orbitrap Fusion ETD

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Ovary, Ovary Cancer Cell

DISEASE(S): Malignant Neoplasm Of Ovary

SUBMITTER: Christopher Hughes

LAB HEAD: Gregg Morin

PROVIDER: PXD003607 | Pride | 2016-10-13

REPOSITORIES: pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	SupplementalScripts_DataObjects_Methods.zip	Other
	ch_04Aug2015_OvCcell-TMT6_HpH_repA1_1.raw	Raw
	ch_04Aug2015_OvCcell-TMT6_HpH_repA1_10.raw	Raw
	ch_04Aug2015_OvCcell-TMT6_HpH_repA1_2.raw	Raw
	ch_04Aug2015_OvCcell-TMT6_HpH_repA1_3.raw	Raw

Items per page:

1 - 5 of 208

Publications

Quantitative Profiling of Single Formalin Fixed Tumour Sections: proteomics for translational research.

Hughes Christopher S CS McConechy Melissa K MK Cochrane Dawn R DR Nazeran Tayyebeh T Karnezis Anthony N AN Huntsman David G DG Morin Gregg B GB

Scientific reports 20161007

Although re-sequencing of gene panels and mRNA expression profiling are now firmly established in clinical laboratories, in-depth proteome analysis has remained a niche technology, better suited for studying model systems rather than challenging materials such as clinical trial samples. To address this limitation, we have developed a novel and optimized platform called SP3-Clinical Tissue Proteomics (SP3-CTP) for in-depth proteome profiling of practical quantities of tumour tissues, including fo ...[more]

PMID: 27713570

Similar Datasets

Project description:Global gene expression patterns associated with early stage endometrial cancer have been reported, but changes in molecular expression associated with tumor grade, depth of myometrial invasion, and non-endometrioid histology have not been previously elucidated. Our group hypothesized there are unique genetic events underlying early endometrial carcinogenesis. Ninety-two samples of pathologically reviewed stage I endometrial cancers (80 endometrioid and 12 serous) with a heterogeneous distribution of grade and depth of myometrial invasion (i.e. 9 IAG1, 14 IAG2, 7 IAG3, 14 IBG1, 12 IBG2, 13 IBG3, 7 ICG1, 10 ICG2, and 6 ICG3) were examined in relation to 12 samples of atrophic endometrium from postmenopausal women. Specimens were analyzed using oligonucleotide microarray analysis and a subset of the differentially expressed transcripts was validated using quantitative PCR. Comparison of early stage cancers with normal endometrium samples by the univariate t-test with 10,000 permutations identified 900 genes that were differentially regulated by at least 4-fold at a p value of <0.001. Unsupervised analysis revealed that when compared to normal endometrium, serous and endometrioid stage I cancers appeared to have similar expression patterns. However, when compared in the absence of normal controls, they were distinct. Differential expression analysis revealed a number of transcripts that were common as well as unique to both histologic types. This data uncovers previously unrecognized, novel pathways involved in early stage endometrial cancers and identifys targets for prevention strategies that are inclusive of both endometrioid and serous histologic subtypes. Ninety-one samples of pathologically reviewed stage I endometrial cancers (79 endometrioid and 12 serous) with a heterogeneous distribution of grade and depth of myometrial invasion (i.e. 9 IAG1, 14 IAG2, 7 IAG3, 14 IBG1, 12 IBG2, 13 IBG3, 7 ICG1, 10 ICG2, and 6 ICG3) were examined in relation to 12 samples of atrophic endometrium from postmenopausal women. Specimens were analyzed using oligonucleotide array analysis.